{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:30:51Z","timestamp":1790134251258,"version":"4.0.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ejim.2020.02.017","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T17:51:57Z","timestamp":1583517117000},"page":"10-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Statins and inflammatory bowel disease: Where do we stand?"],"prefix":"10.1016","volume":"75","author":[{"given":"Spyros","family":"Peppas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Piovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6102-6579","authenticated-orcid":false,"given":"Stefanos","family":"Bonovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2020.02.017_bib0001","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.02.017_bib0002","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.02.017_bib0003","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.02.017_bib0004","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.04.007","article-title":"Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study","volume":"145","author":"Ng","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.02.017_bib0005","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.02.017_bib0006","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.3748\/wjg.v22.i27.6296","article-title":"Environmental risk factors for inflammatory bowel diseases: evidence based literature review","volume":"22","author":"Abegunde","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0007","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","article-title":"Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses","volume":"157","author":"Piovani","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.02.017_bib0008","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2036.2011.04784.x","article-title":"Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study","volume":"34","author":"Chan","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2020.02.017_bib0009","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/ajg.2014.246","article-title":"Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis","volume":"109","author":"Ungaro","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0010","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States From 1999-2012","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2020.02.017_bib0011","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1253\/circj.CJ-10-0110","article-title":"Pleiotropic effects of statins. - Basic research and clinical perspectives -","volume":"74","author":"Zhou","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2020.02.017_bib0012","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(96)05190-2","article-title":"Statins do more than just lower cholesterol","volume":"348","author":"Vaughan","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.02.017_bib0013","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12026-013-8409-8","article-title":"Statins and autoimmunity","volume":"56","author":"Khattri","year":"2013","journal-title":"Immunol Res"},{"key":"10.1016\/j.ejim.2020.02.017_bib0014","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/MIB.0000000000000640","article-title":"Potential Immunomodulatory Effects of Statins in Inflammatory Bowel Disease","volume":"22","author":"Cote-Daigneault","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ejim.2020.02.017_bib0015","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/ibd.21822","article-title":"Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study","volume":"18","author":"Crockett","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ejim.2020.02.017_bib0016","doi-asserted-by":"crossref","first-page":"e5263","DOI":"10.1371\/journal.pone.0005263","article-title":"Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease","volume":"4","author":"Grip","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2020.02.017_bib0017","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/ajg.2016.233","article-title":"Statins associated with decreased risk of new onset inflammatory bowel disease","volume":"111","author":"Ungaro","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0018","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.amjcard.2015.02.035","article-title":"Comparison of frequency of inflammatory bowel disease and noninfectious gastroenteritis among statin users versus nonusers","volume":"115","author":"Khalil","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0019","article-title":"Abstracts of the AGA institute atorvastatin decreases seo index in patients with short duration of disease in ulcerative colitis: a randomized placebo-controlled clinical trial","volume":"130","author":"Higgins","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.02.017_bib0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12664-013-0420-4","article-title":"Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis","volume":"33","author":"Dhamija","year":"2014","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0021","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/bjp.2008.369","article-title":"Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease","volume":"155","author":"Grip","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0022","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1381612822666151109111511","article-title":"All for Statins and Statins for All; An Update","volume":"22","author":"Agouridis","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejim.2020.02.017_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/bs.acc.2015.10.005","article-title":"Biochemistry of Statins","volume":"73","author":"Egom","year":"2016","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.ejim.2020.02.017_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejim.2020.02.017_bib0025","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.jvs.2016.08.094","article-title":"Statin use in patients with peripheral arterial disease","volume":"64","author":"Harris","year":"2016","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejim.2020.02.017_bib0026","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.02.017_bib0027","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2020.02.017_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009217.pub2","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2013","journal-title":"Cochrane database Syst Rev"},{"key":"10.1016\/j.ejim.2020.02.017_bib0029","article-title":"Statins for the primary prevention of coronary heart disease","volume":"2019","author":"Li","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ejim.2020.02.017_bib0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ahj.2018.12.007","article-title":"Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants","volume":"210","author":"Yebyo","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2020.02.017_bib0031","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/2047487313480435","article-title":"Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials","volume":"20","author":"Naci","year":"2013","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0032","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the us preventive services task force","volume":"316","author":"Chou","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2020.02.017_bib0033","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(04)00734-3","article-title":"Stroke prevention, blood cholesterol, and statins","volume":"3","author":"Amarenco","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0034","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/CIRCULATIONAHA.109.874834","article-title":"Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)","volume":"121","author":"Everett","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.02.017_bib0035","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/STROKEAHA.108.534107","article-title":"Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes","volume":"40","author":"Amarenco","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ejim.2020.02.017_bib0036","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/157488609789006949","article-title":"Adverse effects of statins - mechanisms and consequences","volume":"4","author":"Beltowski","year":"2009","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.ejim.2020.02.017_bib0037","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.02.017_bib0038","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2020.02.017_bib0039","doi-asserted-by":"crossref","first-page":"g3743","DOI":"10.1136\/bmj.g3743","article-title":"Non-cardiovascular effects associated with statins","volume":"349","author":"Desai","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2020.02.017_bib0040","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ctrv.2004.06.010","article-title":"Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer","volume":"30","author":"Graaf","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejim.2020.02.017_bib0041","first-page":"10","article-title":"The statins as anticancer agents","volume":"9","author":"Chan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejim.2020.02.017_bib0042","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1200\/JCO.2006.06.3560","article-title":"Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials","volume":"24","author":"Bonovas","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0043","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk: a meta-analysis","volume":"295","author":"Dale","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2020.02.017_bib0044","doi-asserted-by":"crossref","first-page":"543","DOI":"10.7326\/M18-0808","article-title":"Statins and multiple noncardiovascular outcomes: umbrella review of meta-analyses of observational studies and randomized controlled trials","volume":"169","author":"He","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2020.02.017_bib0045","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S1470-2045(14)70119-6","article-title":"Statins and breast cancer prognosis: evidence and opportunities","volume":"15","author":"Ahern","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0046","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1050-1738(00)00044-X","article-title":"Direct vascular effects of HMG-CoA reductase inhibitors","volume":"10","author":"Laufs","year":"2000","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.ejim.2020.02.017_bib0047","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.4065\/77.10.1085","article-title":"Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit","volume":"77","author":"Wright","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2020.02.017_bib0048","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2007.11.036","article-title":"Statins in tumor suppression","volume":"260","author":"Sassano","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejim.2020.02.017_bib0049","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2016.71.3594","article-title":"Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study","volume":"35","author":"Pursnani","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0050","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1158\/0008-5472.CAN-05-4061","article-title":"Breast cancer growth prevention by statins","volume":"66","author":"Campbell","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejim.2020.02.017_bib0051","doi-asserted-by":"crossref","first-page":"43586","DOI":"10.1074\/jbc.M307194200","article-title":"p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases","volume":"278","author":"Ukomadu","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejim.2020.02.017_bib0052","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1097\/00029330-200809010-00018","article-title":"Simvastatin attenuates lipopolysaccharide-induced airway mucus hypersecretion in rats","volume":"121","author":"Ou","year":"2008","journal-title":"Chin Med J"},{"key":"10.1016\/j.ejim.2020.02.017_bib0053","doi-asserted-by":"crossref","first-page":"L592","DOI":"10.1152\/ajplung.00386.2007","article-title":"Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients","volume":"294","author":"Murphy","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0054","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.antiviral.2013.06.018","article-title":"Treating influenza with statins and other immunomodulatory agents","volume":"99","author":"Fedson","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ejim.2020.02.017_bib0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0021-9150(02)00194-6","article-title":"Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells","volume":"165","author":"Ito","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2020.02.017_bib0056","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1089\/vim.2005.18.474","article-title":"Statins could be used to control replication of some viruses, including HIV-1","volume":"18","author":"Gilbert","year":"2005","journal-title":"Viral Immunol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0057","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/01.ATV.0000163840.63685.0c","article-title":"Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins","volume":"25","author":"Arnaud","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0058","doi-asserted-by":"crossref","first-page":"e11304","DOI":"10.1097\/MD.0000000000011304","article-title":"Statins use and risk of dementia: A dose-response meta analysis","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.ejim.2020.02.017_bib0059","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ejim.2015.08.012","article-title":"Do statins prevent Alzheimer's disease? A narrative review","volume":"26","author":"Daneschvar","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.02.017_bib0060","first-page":"69","article-title":"The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis","volume":"33","author":"Lv","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0061","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(04)16205-3","article-title":"Oral simvastatin treatment in relapsing-remitting multiple sclerosis","volume":"363","author":"Vollmer","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.02.017_bib0062","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10067-014-2654-7","article-title":"Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial","volume":"33","author":"Fatemi","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0063","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ejim.2016.11.008","article-title":"Statins for inflammatory bowel disease: Can off-label drug help it?","volume":"38","author":"Bifulco","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.02.017_bib0064","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.12902","article-title":"Immune modulatory effects of statins","volume":"154","author":"Zeiser","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.ejim.2020.02.017_bib0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3324\/haematol.2012.065789","article-title":"Inhibition of protein geranylgeranylation and farnesylation protects against GvHD via effects on CD4 effector T cells","volume":"98","author":"Hechinger","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2020.02.017_bib0066","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lfs.2015.04.004","article-title":"Ezetimibe and simvastatin modulate gut microbiota and expression of genes related to cholesterol metabolism","volume":"132","author":"Catry","year":"2015","journal-title":"Life Sci"},{"key":"10.1016\/j.ejim.2020.02.017_bib0067","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cgh.2016.02.017","article-title":"Statin use is associated with reduced risk of colorectal cancer in patients with inflammatory bowel diseases","volume":"14","author":"Ananthakrishnan","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0068","first-page":"997","article-title":"Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice","volume":"17","author":"Naito","year":"2006","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.ejim.2020.02.017_bib0069","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s10620-007-0102-0","article-title":"Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis","volume":"53","author":"Ikeda","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ejim.2020.02.017_bib0070","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/08923973.2011.559475","article-title":"The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis","volume":"33","author":"Aktunc","year":"2011","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0071","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1124\/jpet.102.044099","article-title":"The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis","volume":"305","author":"Sasaki","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejim.2020.02.017_bib0072","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.intimp.2006.10.013","article-title":"Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis","volume":"7","author":"Lee","year":"2007","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0073","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/89058","article-title":"Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site","volume":"7","author":"Weitz-Schmidt","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.ejim.2020.02.017_bib0074","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00011-007-6177-4","article-title":"Disease modifying effect of statins in dextran sulfate sodium model of mouse colitis","volume":"57","author":"Kanagarajan","year":"2008","journal-title":"Inflamm Res"},{"key":"10.1016\/j.ejim.2020.02.017_bib0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.phrs.2014.03.001","article-title":"Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases","volume":"88","author":"Ulivieri","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejim.2020.02.017_bib0076","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/ajg.2016.412","article-title":"Statins and the risk of inflammatory bowel disease","volume":"111","author":"Dai","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0077","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/ajg.2016.338","article-title":"Editorial: statins for inflammatory bowel disease: expanding the scope of prevention","volume":"111","author":"Khalili","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.017_bib0078","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/EDE.0b013e3182093a0f","article-title":"Time-window bias in case-control studies: statins and lung cancer","volume":"22","author":"Suissa","year":"2011","journal-title":"Epidemiology"},{"key":"10.1016\/j.ejim.2020.02.017_bib0079","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"Levesque","year":"2010","journal-title":"BMJ"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520300613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520300613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:30:59Z","timestamp":1760607059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520300613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":79,"alternative-id":["S0953620520300613"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.02.017","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins and inflammatory bowel disease: Where do we stand?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}